Conference Reports for NATAP

Back

Conference on Retroviruses and Opportunistic Infections Virtual February 12-16, 2022     Summary from virtual CROI 2022 for HIV and liver disease Hepatitis elimination for 2030 on track? Is fatty liver disease a growing concern? New insights from CROI 2022. - Prof. Dr. Jurgen K. Rockstroh Department of Medicine I University Hospital Bonn Venusberg-Campus 1 53127 Bonn Germany - (03/21/22)   Clinical Pharmacology at CROI 2022 - Courtney V. Fletcher, Pharm.D. Professor UNMC Center for Drug Discovery University of Nebraska Medical Center - (03/28/22)   CROI 2022 and HIV prevention - NATAP Report by Renee Heffron, PhD and Connie Celum, MD, University of Washington (03/28/22)   HIV Prevention and Resistance on PrEP - By Christina K. Psomas MD PhD - (04/20/22)   Oral TDF/FTC Provides Early Mucosal Protection In Both On- Demand And Daily Regimen - (04/01/22)   Contributions to the Decline in HIV Incidence among GBM in the UK: A Modelling Study - HIV Elimination in 25 Years - (03/31/22)   DEEPHIV: DEEP LEARNING TO PREDICT DDI RELEVANCE FOR ARVS - (03/31/22)   Machine Learning Quantifies Accelerated White Matter Aging in Persons with HIV - (03/31/22)   Long acting doravirine for treatment and prevention of vaginal HIV transmission - (03/30/22)   Long acting doravirine for treatment and prevention of vaginal HIV transmission - (03/30/22)   CROI 2022 Key Aging & Comorbidities Highlights - (03/28/22)   CROI 2022 Aging & HIV Symposium - (03/28/22)   EFFICACY & SAFETY OF RAVIDASVIR + SOFOSBUVIR IN HEPATITIS C: STORM-C-1 FINAL RESULTS - (03/24/22)   CROI Symposium: Aging & HIV "care of PLWH has NOT kept up with the reality of this aging population" - (03/23/22)   IMPACT OF SVR WITH DAAs IN COINFECTED PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS - (03/22/22)   ADHERENCE IN THE ACTG A5360 HCV MINIMAL MONITORING (MINMON) TRIAL - (03/22/22)   CANNABIS USE AND HEPATIC STEATOSIS BY MRI-PDFF - (03/22/22)   Regional Variation in HBV Prevalence in People Living with HIV in Botswana - (03/22/22)   LOW RATES OF HEPATITIS B VACCINATION AMONG PEOPLE WITH HIV - (03/22/22)   Randomized Trial of HBV Revaccination in MSM Born in the Neonatal Vaccination Era - (03/22/22)   NEW HEPATITIS B INFECTION AMONG HIV PATIENTS: WHO IS AT RISK? - (03/21/22)   Progress toward HCV microelimination among HIV-positive patients in Taiwan - (03/21/22)   ACTG A5324: A RANDOMIZED TRIAL OF ART INTENSIFICATION FOR COGNITIVE IMPAIRMENT IN PWH - Mark Mascolini (03/21/22)   FEASIBILITY AND VIRAL RESPONSE TO TREATING ACUTE/EARLY HIV IN A MULTINATIONAL STUDY - (03/21/22)   IMPACT OF SVR WITH DAAs IN COINFECTED PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS - (03/21/22)   Integration of HIV and HCV Services with Medication for Opioid Use Disorder in the U.S. - (03/21/22)   Integration of HIV and HCV Services with Medication for Opioid Use Disorder in the U.S. - (03/18/22)   A RETROSPECTIVE ANALYSIS OF BONE LOSS IN EMTRICITABINE/TENOFOVIR THERAPY FOR HIV PrEP - (03/18/22)   SARS-CoV-2 CSF N Antigen Detection is Associated with CNS Inflammation in Neuro-COVID - (03/15/22)   NIH Launches Clinical Trial of Three mRNA HIV Vaccines - (03/14/22)   HIV-1 RNA TRANSCRIPTS IN CSF CD4+ T CELLS, NOT MONOCYTES, ARE LINKED TO BRAIN INJURY - (03/14/22)   Treatment with Broadly Neutralizing Antibodies in Children with HIV in Botswana (The Tatelo Study) - (03/11/22)   NON-OBESE NAFLD IS ASSOCIATED WITH HIGHER SCD14 CONCENTRATIONS IN ADULTS WITH HIV - (03/11/22)   11% - HIGH INCIDENCE RATE OF CT-MEASURED NAFLD IN MACS MEN WITH AND WITHOUT HIV INFECTION - (03/11/22)   DETERMINANTS OF LIVER STEATOSIS IN PEOPLE LIVING WITH HIV ON ANTIRETROVIRAL THERAPY - ALT matters - (03/11/22)   IMPACT OF NASH ON THE SURVIVAL OF PEOPLE LIVING WITH HIV - (03/11/22)   PREVALENCE OF NONALCOHOLIC FATTY LIVER DISEASE VERTICALLY HIV-INFECTED YOUTHS - (03/11/22)   Effect of Tenofovir on T-cell Maturational Subsets in Long Term Aviraemic HIV Adults - (03/11/22)   NEUROSYMPTOMATIC HIV-1 CSF ESCAPE ASSOCIATES WITH REPLICATION IN CNS CD4+ T CELLS - (03/11/22)   PBR28 PET IMAGING IN PEOPLE WHO STARTED ART DURING ACUTE VERSUS CHRONIC HIV INFECTION - (03/07/22)   HPV Genotyping in a Study of Adjunctive Vaccine For Treatment of Cervical Dysplasia - (03/07/22)   STATIN USE IN ART-TREATED HIV REVEALS AN ALTERED MACROPHAGE TRANSCRIPTOMIC PROFILE - (03/04/22)   PREVALENCE OF ANEMIA AND RISK FACTORS IN PEOPLE WITH HIV IN THE MODERN ART ERA: aging, Blacks, women, Hispanics have higher risk - (03/04/22)   Impaired response of memory Treg to HDL is associated with high cardiovascular disease risk in persons with HIV - (03/04/22)   Carl Dieffenbach Highlights Aging & Comorbidities for PLWH, Frailty & Research & the Need for Better Care: "care of people living with HIV has NOT kept up with the reality of this aging population" - (03/04/22)   PERINATAL HIV-1 TRANSMISSION IN FRANCE: U=U FOR MOTHERS ON ART FROM CONCEPTION....no perinatal transmission in this analysis - (03/03/22)   LONG-ACTING INJECTABLE FOR PREVENTION OF HIV AND UNPLANNED PREGNANCY - (03/02/22)   PERINATAL HIV-1 TRANSMISSION IN FRANCE: U=U FOR MOTHERS ON ART FROM CONCEPTION - (03/02/22)   Phase 2b Efficacy Trial of Mosaic HIV-1 Vaccine Regimen in African Women (Imbokodo) - (03/02/22)   ARCHIVED RESISTANCE AND RESPONSE TO <40 C/ML AND TND - DTG/3TC FDC AT WEEK 48 IN SALSA - (03/01/22)   Estimating the Lifetime Risk of a Diagnosis of HIV Infection in the United States, Blacks have highest risk - (03/01/22)   Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques Ad26/MVA+PGT121+Vesatolimod - (03/01/22)   Development of Viral Biomarkers in SHIV Infected Non-Human Primates in Reservoirs - (03/01/22)   Adolescent and Parent Experiences with Long-acting Injectables in the MOCHA Study - (03/01/22)   The FUNCFRAIL Score to discriminate Frailty in Older Adults with HIV - (02/28/22)   Potent Targeted Activator of Cell Kill (TACK) Molecules Eliminate HIV Infected Cells - (02/28/22)   2DR vs. 3DR INTEGRASE INHIBITOR-BASED REGIMENS INITIATION AND CD4+/CD8+ RATIO RECOVERY - (02/26/22)   CORONARY FLOW RESERVE ON DTG/ABC/3TC AT BASELINE AND AFTER SWITCH TO BIC/FTC/TAF - (02/26/22)   EFdA OFFERS COMPLETE PROTECTION FROM REPEATED PENILE HIV CHALLENGES - (02/26/22)   Association of Sleep Disruption with Kynurenine Pathway Activation in Women Living with HIV - (02/26/22)   Lifetime HIV Risk 1 in 120 in US, Highest in Black and Hispanic Males - Mark Mascolini (02/26/22)   REVERSIBILITY OF CENTRAL NERVOUS SYSTEM ADVERSE EVENTS IN COURSE OF ART - (02/25/22)   Atrial Fibrillation Risk Factors Among Patients in HIV Care in the United States - (02/25/22)   Sleep and Frailty Among Men with and Without HIV - poor sleep for PLWH - (02/25/22)   POOR SLEEP IS LINKED TO CVD RISK IN PLWH IN A SOUTHWESTERN US CLINIC - 40% Have Sleeping Difficuties - (02/25/22)   A novel comorbidity index predicts cognitive change in people with chronic HIV - (02/24/22)   CROI Aging Symposium 2022 - Jules Levin slides, talk - NATAP - National AIDS Treatment Advocacy Project (02/24/22)   Impact of Rheumatologic Therapies on Cardiovascular Outcomes in People with HIV (02/24/22)   Inflammatory clusters are associated with multimorbidity and Cardiovascular disease in People with HIV on effective treatment (02/24/22)   Effects of Air Pollutants on Neuroimaging Measures Diverge by HIV Status: poverty-neighborhood area & HIV effect brain structure (02/24/22)   HIV-INDUCED CELLULAR SENESCENCE IN PLWH IS DECREASED EX VIVO BY D+Q SENOLYTIC DRUGS (02/24/22)   Associations Between Plasma Biomarkers and Neurocognition in ART-Treated PWH (02/24/22)   COUNTERFACTUAL ESTIMATION OF CAB-LA EFFICACY AGAINST PLACEBO USING EXTERNAL TRIAL DATA (02/24/22)   INFLAMMATION AND IMMUNE ACTIVATION NOT DRIVEN BY ON-ART HIV-SPECIFIC IMMUNE RESPONSES - "Die is Cast Before ART" HIV Long-Lasting Immune Dysreguation (02/24/22)   A RANDOMIZED TRIAL OF DTG PLUS DRV/c AS A SWITCH STRATEGY IN SUBJECTS WITH MDR HIV-1 (02/24/22)   Associations Between Plasma Biomarkers and Neurocognition in ART-Treated PWH (02/24/22)   PRECLINICAL STUDIES TOWARD A PHASE I/IIA TRIAL USING ANTI-HIV DUOCAR-T CELL THERAPY (02/24/22)   Choice and Adherence to Dapivirine Ring or Oral PrEP by Young African Women in REACH (02/23/22)   The Bi-directional Effects of Hormone Therapy and PrEP in Transgender Individuals (02/23/22)   NEURAL TUBE DEFECTS AND PRENATAL EXPOSURE TO DOLUTEGRAVIR: UNITED STATES, 2008-2019 (02/23/22)   No Interactions Between Hormone Therapy and PrEP in Transgender Women or Men - Mark Mascolini (02/23/22)   IMPACT OF MATERNAL HIV/HBV CO-INFECTION ON PREGNANCY AND INFANT OUTCOMES (02/23/22)   The role of HIV/HBV/HCV triple infection in end stage liver disease (ESLD) and all cause mortality in Europe (02/23/22)   Growth of infants with perinatal exposure to maternal DTG vs EFV and TDF vs TAF: the randomized IMPAACT 2010 trial - (02/22/22)   ACTG A5351s: Effect of Immune-Modulatory Interventions on CMV Replication during ART - (02/22/22)   More Adverse Birth Outcomes With COVID Plus HIV in Botswana - Mark Mascolini (02/22/22)   Post-COVID19 Quality of Life: Low Satisfaction With Physical and Mental Health Status - (02/22/22)   SARS-CoV-2 Prevalence Similar in Adults and Children in 15-Site US Study - Mark Mascolini (02/22/22)   From NAFLD to MAFLD: implications of change in terminology in PWH - (02/22/22)   NAFLD IS COMMON AND ASSOCIATED WITH CARDIOVASCULAR RISK IN REPRIEVE PARTICIPANTS - (02/22/22)   PrEP Indications and PrEP Knowledge, Access, and Interest Among Individuals with HCV - (02/22/22)   HCV MICROELIMINATION AMONG PEOPLE LIVING WITH HIV IN SAN DIEGO: ARE WE ON TRACK? - (02/22/22)   HBIg-Free Strategy Prevents Vertical HBV Transmission-If Mothers Start TDF Soon Enough - Mark Mascolini (02/22/22)   Proteinuria Is Common Among People with HIV With Controlled Viremia - (02/22/22)   MUSCLE QUALITY AND PHYSICAL FUNCTION IN MEN WITH AND WITHOUT HIV - (02/22/22)   IS THERE A ROLE OF NOVEL ART REGIMENS IN THE DECLINING PREVALENCE OF HAND? HAND 22% Today in Italy- Asymptomatic Remains Prevalent 10%-24% - (02/22/22)   SERUM AND CSF ULTRA-SENSITIVE DETECTION OF NFL AND ALZHEIMER'S BIOMARKERS IN PLWH - (02/22/22)   Triple & Double bNAbs Studies - (02/21/22)   Injectable, Biodegradable, Removable PrEP/Contraceptive Tested in Mice - Mark Mascolini (02/21/22)   HIV-Infected Cells Recirculate Throughout Organs During Suppressive ART - Mark Mascolini (02/21/22)   Lenacapavir Shots or Tabs Control HIV in First-Line ART Combinations - Mark Mascolini (02/21/22)   Most Large HIV Molecular Clusters in US Primarily Involve MSM - Mark Mascolini (02/21/22)   Dolutegravir Pharmacokinetics In People with HIV Receiving Daily 1HP for Latent TB Treatment (ACTG A5372) - (02/20/22)   The Impact of COVID-19 on Adverse Birth Outcomes in Botswana by HIV Status - (02/20/22)   Role of Renin-Angiotensin-Aldosterone System Activation in Arterial Inflammation in HIV - (02/20/22)   DURABILITY OF SARS-COV-2 mRNA VACCINE IMMUNE RESPONSE IN PLWH WITH ADVANCED DISEASE - (02/18/22)   Immunogenicity and reactogenicity to COVID-19 mRNA vaccine additional dose in PLWH - (02/18/22)   SARS-CoV-2 Vaccine Immunogenicity in PLWH in The Netherlands & age, CD4, HIV viral load effects - (02/18/22)   Sotrovimab mAb Limits Progression to Severe COVID Regardless of Serostatus - Mark Mascolini (02/18/22)   Intramuscular Sotrovimab Noninferior to IV for Mild/Moderate COVID - Mark Mascolini (02/18/22)   One Quarter Ordering Free HIV Self-Tests in US Never Tested Before - Mark Mascolini (02/18/22)   Choice and Adherence to Dapivirine Ring or Oral PrEP by Young African Women in REACH: 67% prefer ring vs 31% oral PrEP - (02/18/22)   PHASE III TRIAL OF MOLNUPIRAVIR IN ADULTS WITH MILD SARS-COV2 INFECTION IN INDIA - (02/18/22)   PREDICTORS OF NEURODEVELOPMENT IN HIV-EXPOSED UNINFECTED INFANTS - (02/18/22)   Casirivimab and Imdevimab Combination Provides Long-Term Protection Against COVID-19 - phase 3 study in preventing COVID in household contacts of infected individuals - (02/18/22)   Camostat Does Not Relieve COVID Symptoms or Clear Virus in Placebo Trial - Mark Mascolini(02/17/22)   Dolutegravir Reversibly Induces Mitochondrial Fragmentation and Toxicity In Vitro - (02/17/22)   IMPROVING INTESTINAL BARRIER USING GLP-2 AGONIST REDUCES ARTERIAL INFLAMMATION IN PWH - (02/16/22)   Dual Monoclonal Antibody Cuts COVID Risk in 8-Month Placebo Trial - Mark Mascolini (02/16/22)   COVID-19 BOOSTER VACCINE EFFECTIVENESS IN PEOPLE WITH AND WITHOUT IMMUNE DYSFUNCTION - in reducing breakthrough, duration of benefit (02/16/22)   00136: A RANDOMIZED TRIAL OF SWITCHING TREATMENT-EXPERIENCED ADULTS FROM PI/r TO DTG - (02/17/22)   Bolstering ART With DTG +/- MVC Does Not Help Neurocognitive Performance - Mark Mascolini (02/16/22)   Universal hepatitis C virus screening in pregnancy HCV Testing Quadruples With Switch to Universal Screening in Pregnancy - Mark Mascolini(02/16/22)   LONGITUDINAL MODELING OF EARLY HIV BURDEN IN THE CENTRAL NERVOUS SYSTEM (02/16/22)   New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor - press release (02/16/22)   Lenacapavir as part of a Combination Regimen in Treatment-Naï ve People with HIV: Week 54 Results (02/16/22)   Big Drops in HIV/STI Testing (But Sometimes Not Diagnoses) When COVID Arrived - Mark Mascolini (02/16/22)   African NADIA Trial Favors 2nd-Line TDF Over ZDV, and DRV/r Over DTG - Mark Mascolini (02/16/22)   Switching From NNRTI to DTG-Even With Same NRTIs-Superior to PI - Mark Mascolini (02/16/22)   Phase 1 Study of Long-Acting 3BNC117 and 10-1074 in Viremic Adults Living With HIV (02/16/22)   Lenacapavir as part of a Combination Regimen in Treatment-Naï ve People with HIV: Week 54 Results (02/16/22)   PHASE I PK, SAFETY, AND ACCEPTABILITY STUDY OF A 90-DAY TENOFOVIR VAGINAL RING (02/16/22)   EFFECT OF DIRECT-ACTING ANTIVIRALS ON HCV INCIDENCE AMONG PEOPLE LIVING WITH HIV (02/16/22)   COVID Pushes USA Farther Off Course to Meet HCV Elimination Goals - Mark Mascolini (02/16/22)   Asymptomatic SARS-CoV-2 Infection is Extremely Common among People with HIV (02/16/22)   Long COVID Definition - POST-ACUTE SEQUELAE OF SARS-COV-2: CLINICAL CONDITION COMPARISON IN A MATCHED COHORT (02/16/22)   COVID Symptoms Reported Lasting Longer in US Than South Africa, Peru - Mark Mascolini (02/16/22)   Treatment of anal high-grade squamous intraepithelial lesions to prevent anal cancer (02/15/22)   Treating Anal Lesions in HIV+ Cuts Anal Cancer Rate 57% in Randomized Trial - Mark Mascolini (02/15/22)   Outpatient Clinics Efficient in Spotting Recent HIV in 3 African Countries - Mark Mascolini (02/15/22)   RNA Assay Spots HIV Earlier in CAB-LA PrEP Users, May Avert Resistance - Mark Mascolini (02/15/22)   CAB-LA PrEP Keeps Advantage Over TDF/FTC in 1-Year Unblinded Phase- Seven Breakthrough Infections Despite On-Time CAB-LA Injections - Mark Mascolini (02/15/22)   ISLATRAVIR DISTRIBUTION IN MUCOSAL TISSUES, PBMC & PLASMA AFTER MONTHLY ORAL DOSING (02/15/22)   PHASE IIA TRIAL OF ISLATRAVIR QM FOR HIV PrEP: WEEK 24 METABOLIC AND RENAL OUTCOMES (02/15/22)   THE IMPACT OF 3BNC117 AND ROMIDEPSIN TREATMENT AT ART INITIATION ON HIV-1 PERSISTENCE - Mark Mascolini (02/15/22)   Long COVID Definition - Cardiac Rhythm Upsets, Diabetes, GU Symptoms Emerge as Persistent COVID Problems (02/15/22)   ANGIOGENIC FACTORS IN RNA-SEQ OF SKIN AND GASTROINTESTINAL KAPOSI SARCOMA LESIONS (02/15/22)   NONSMALL CELL LUNG CARCINOMA IN PLWH HARBORS IMMUNOREGULATORY TUMOR MICROENVIRONMENT (02/15/22)   GUT MICROBIOTA, PLASMA METABOLOMICS, AND ATHEROSCLEROSIS IN HIV INFECTION (02/15/22)   MI Risk Not Falling in HIV Group, as It Is in non-HIV Peers - Mark Mascolini (02/15/22)   CROI Monday Feb 14: 5 Key Aging & Metabolic Oral Presentation Studies - (02/15/22)   TENOFOVIR ALAFENAMIDE IS ASSOCIATED WITH SHORTER TELOMERE LENGTH IN PEOPLE WITH HIV - (02/15/22)   Macrophage-specific arterial infiltration relates to plaque type and immune activation in HIV - (02/14/22)   PLWH Have Higher levels of Fat Tissue Fibrosis - INFLAMMATION AND KYNURENINE PATHWAY LINKED TO TYPE 2 DIABETES AND FAT FIBROSIS IN HIV - (02/14/22)   Trends in Myocardial Infarction Risk by HIV Status in Two US Healthcare Systems - (02/14/22)   One Third on ART 48 Hours From Birth Eligible for ART Interruption - Mark Mascolini (02/14/22)   TREATMENT WITH SOF/VEL/VOX IN HIV-HCV COINFECTED PATIENTS PREVIOUSLY EXPOSED TO DAAs - (02/14/22)   Impact of HCV cure on depressive symptoms in the HIV-HCV co-infected population - (02/14/22)   Two or More Anticholinergics Tied to Falls, Frailty in People With HIV - Mark Mascolini (02/14/22)   Geographical Differences in Functional Impairment of PLWH: Over One Third in Global HIV Analysis Have Impaired Physical Function - Mark Mascolini (02/14/22)   IV PUSH ADMINISTRATION OF IBALIZUMAB: PHARMACOKINETICS, SAFETY, AND EFFICACY - (02/14/22)   Infant Stunting Worse With Maternal EFV Than DTG, Similar With TAF and TDF - Mark Mascolini (02/14/22)   IMPACT OF TREATMENT INTERRUPTION ON COLONIC MUCOSA IN ACUTELY TREATED PARTICIPANTS - (02/14/22)   COVID Vax More Likely in Older, Heavier Men (vs Women) in Global HIV Trial - Mark Mascolini (02/14/22)   COVID mRNA Vaccines Appear to Protect Against Infection Transmission - Mark Mascolini (02/14/22)   COVID Vax Booster Cuts Breakthrough Infections, Hospital Use, Death - Mark Mascolini (02/14/22)   Post-Acute Long COVID: Lower Heart Rates During Exercise Point to Autonomic Dysfunction Causing Symptoms - Mark Mascolini (02/14/22)   Impact of the COVID-19 Pandemic on HIV Outpatient Care and Viral Suppression in NYC - (02/14/22)   PREVALENCE OF ANEMIA AND RISK FACTORS IN PEOPLE WITH HIV IN THE MODERN ART ERA - (02/14/22)   Assessing health-related quality of life in people with HIV and cognitive issues - (02/13/22)   Impact of COVID outbreak on prevention and care for HIV and other STI's at a large hospital - (02/13/22)   SARS-COV-2 VACCINATION: IMPACT ON HIV-1 RNA LEVELS AND ANTIBODY RESPONSE AMONG PLWH - (02/13/22)   PETRAM RESULTS: BONE TURNOVER CHANGES ON 18F-NaF PET/CT AFTER A RANDOMISED SWITCH TO TAF - (02/13/22)   Decreased Myelin Content and Cognitive Performance in Adults with Perinatal HIV - (02/13/22)   SAFETY AND PK OF LONG-ACTING CABOTEGRAVIR AND RILPIVIRINE IN ADOLESCENTS - (02/13/22)   EFFECT OF L74I POLYMORPHISM ON FITNESS OF HIV-1 SUBTYPE A6 RESISTANT TO CABOTEGRAVIR - (02/13/22)   Birth Outcomes following Prenatal Exposure to Dolutegravir: the Dolomite-EPPICC study - (02/13/22)   IMPAACT 2019: PK & Safety of Dispersible ABC/DTG/3TC in Children with HIV 6 to <14kg - (02/13/22)   COGNITIVE PREDICTORS OF EVERYDAY FUNCTIONING IN THE WOMEN'S INTERAGENCY HIV STUDY - (02/12/22)   ADHERENCE TO ANTIRETROVIRAL THERAPY IN MEDICARE FEE-FOR-SERVICE BENEFICIARIES WITH HIV - (02/12/22)   Islatravir does not prolong QTc in a thorough QT study in healthy participants - (02/12/22)   Kinetics of Lenacapavir in Participants With Severe Renal Impairment - (02/12/22)   Evaluation of Potential Drug-Drug Interactions Between Islatravir and Lenacapavir - (02/12/22)   Absence of Cross-Resistance to Lenacapavir in HIV Entry Inhibitor-Resistant Isolates - (02/12/22)   Immunogenicity and Prophylactic Efficacy of Arenavirus-Based SIV Vaccine in Macaques - (02/12/22)   LONG ACTING LENACAPAVIR PROTECTS AGAINST INTRAVENOUS CHALLENGE WITH SIMIAN-TROPIC HIV - (02/12/22)   WEEK 48 METABOLIC HEALTH AFTER SWITCH TO DTG/3TC VS CAR BY BASELINE REGIMEN (SALSA) - (02/12/22)   B/F/TAF Five-Year Outcomes in Treatment-Naïve Adults - (02/12/22)   COVID-19 and the HIV continuum in people living with HIV enrolled in Collaborating Consortium of Cohorts Producing NIDA Opportunities (C3PNO) cohorts - (02/12/22)   Long-Acting Lenacapavir in People With Multidrug-Resistant HIV-1: Week 52 Results - (02/12/22)   FEMINIZING HORMONAL THERAPIES WORSEN CARDIOMETABOLIC PROFILES IN TRANSGENDER WOMEN - (02/12/22)   IMPACT OF INTEGRASE STRAND TRANSFER INHIBITORS ON COGNITION IN THE HAILO COHORT - (02/12/22)   Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression at Five Years, in Treatment-Naïve Adults - (02/12/22)   Abnormal cognitive aging is detected despite clinically defined cognitive stability - (02/12/22)   LONG-ACTING CABOTEGRAVIR+RILPIVIRINE EVERY 2 MONTHS: ATLAS-2M WEEK 152 RESULTS - (02/12/22)   VIIV HEALTHCARE TO PRESENT NEW LONG-TERM FINDINGS FROM ITS INNOVATIVE 2-DRUG AND LONG-ACTING HIV MEDICINES PORTFOLIO AT CROI 2022 - (02/12/22)   Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressing Urgent Global Needs - (02/12/22)